Organogenesis Holdings Inc. (NASDAQ:ORGO) Position Cut by BNP Paribas Financial Markets

BNP Paribas Financial Markets lowered its holdings in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) by 18.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 97,917 shares of the company’s stock after selling 21,645 shares during the period. BNP Paribas Financial Markets owned approximately 0.07% of Organogenesis worth $280,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Pallas Capital Advisors LLC acquired a new position in shares of Organogenesis during the second quarter valued at $38,000. Delap Wealth Advisory LLC acquired a new position in Organogenesis during the 2nd quarter valued at about $40,000. Intech Investment Management LLC bought a new stake in shares of Organogenesis during the 3rd quarter worth about $43,000. Allspring Global Investments Holdings LLC lifted its stake in shares of Organogenesis by 4,989.9% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 15,677 shares of the company’s stock worth $44,000 after acquiring an additional 15,369 shares during the period. Finally, Mackenzie Financial Corp boosted its holdings in shares of Organogenesis by 46.1% in the second quarter. Mackenzie Financial Corp now owns 24,328 shares of the company’s stock valued at $68,000 after acquiring an additional 7,678 shares in the last quarter. Institutional investors own 49.57% of the company’s stock.

Organogenesis Price Performance

NASDAQ ORGO opened at $3.40 on Monday. Organogenesis Holdings Inc. has a 12 month low of $2.16 and a 12 month high of $4.70. The firm has a market capitalization of $450.77 million, a PE ratio of -56.67 and a beta of 1.73. The company’s 50 day simple moving average is $3.43 and its 200 day simple moving average is $2.99. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74.

Organogenesis (NASDAQ:ORGO) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.11. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. The company had revenue of $115.18 million for the quarter, compared to analysts’ expectations of $109.59 million. During the same period last year, the firm earned $0.02 EPS. As a group, equities research analysts forecast that Organogenesis Holdings Inc. will post -0.07 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Gary S. Gillheeney sold 157,448 shares of the firm’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $3.64, for a total transaction of $573,110.72. Following the completion of the sale, the chief executive officer now directly owns 3,143,753 shares of the company’s stock, valued at $11,443,260.92. This trade represents a 4.77 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold 216,916 shares of company stock worth $784,832 in the last ninety days. 36.90% of the stock is currently owned by corporate insiders.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.